FIELD: medicine; oncology.
SUBSTANCE: present invention discloses the use of an mTOR inhibitor in inhibiting activation of proteins in the PI3K/Akt/mTOR signaling pathway, characterized by that the mTOR inhibitor comprises carrimycin or isovaleryl-spiramycin I.
EFFECT: ability of carrimycin to inhibit proteins of PI3K/Akt/mTOR signaling pathways.
11 cl, 14 dwg, 2 tbl, 3 ex
| Title |
Year |
Author |
Number |
| APOPTOSIS-INDUCING MEANS |
2011 |
- Niitsu Joshiro
- Nishita Khiroki
|
RU2639459C2 |
| THE USE OF CARRIMYCIN AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS FOR THE PRODUCTION OF MEDICINES FOR TREATMENT AND / OR TUMOR PREVENTION |
2018 |
- Dzhiang, Enkhong
- Ksia, Mingyu
- Dzhiang, Ksyunlej
- Dzhiang, Ksyundong
|
RU2746047C1 |
| IMPROVED COMPOSITIONS BASED ON T-CELLS |
2015 |
|
RU2719030C2 |
| USE OF ISOVALERYL-SPIRAMYCIN I, II AND/OR III IN MANUFACTURE OF DRUG FOR TREATMENT AND/OR PREVENTION OF TUMOR AND PREPARATION OF DRUG |
2018 |
- Dzhiang, Enkhong
- Khe, Vejking
- Dai, Dzhianlyu
- Dzhiang, Yang
- Dzhiang, Ksyunlej
- Zhao, Ksiaofeng
|
RU2766176C2 |
| METHOD OF PRODUCTION OF T-CELLS |
2015 |
|
RU2813668C2 |
| TREATING CANCER WITH COMBINATION OF RADIATION THERAPY, CERIUM OXIDE NANOPARTICLES AND CHEMOTHERAPEUTIC AGENT |
2015 |
|
RU2704811C2 |
| COMBINED THERAPY WITH AFUCOSYLATED CD20 ANTIBODY AND mTOR INHIBITOR |
2011 |
- Gerting Frank
- Klyajn Kristian
|
RU2585489C2 |
| USE OF MYOSTATIN ANTAGONISTS, COMBINATION CONTAINING THEM AND THEIR USE |
2016 |
- Klickstein, Lloyd B.
- Roubenoff, Ronenn
- Feige, Jerome
- Trifilieff, Estelle
|
RU2781401C2 |
| AGENT INDUCING CELL DEATH, CELL GROWTH INHIBITING AGENT, AND PHARMACEUTICAL COMPOSITION FOR TREATING DISEASE CAUSED BY ABNORMAL CELL GROWTH |
2015 |
- Niitsu Yoshiro
- Minomi Kenjirou
- Tanaka Hiroyuki
|
RU2707746C2 |
| SYNERGISTIC COMBINATIONS OF AURISTANE |
2015 |
|
RU2717570C2 |
